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Abstract
Dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1)-p70 ribosomal 
protein kinase 1 (S6K1) signaling pathway occurs frequently in acute myeloid leukemia (AML) 
patients. This pathway also plays a critical role in maintaining normal cellular processes. Given 
the importance of leukemia stem cells (LSC) in the development of minimal residual disease 
(MRD), it is critical to use therapeutic interventions that target LSC population to prevent disease 
relapse. mTORC1-S6K1 pathway has been identified as an important regulator of hematopoietic 
stem cell (HSC) and LSC functions. Both HSC and LSC functions require regulation of key 
cellular processes including proliferation, metabolism and autophagy, which are regulated by 
mTORC1 pathway. Despite mTORC1-S6K1 pathway being a critical regulator of AML initiation 
and progression, inhibitors of this pathway alone have yielded mixed results in clinical studies. 
Recent studies have identified strategies to develop new mTORC1-S6K1 inhibitors like 
RapaLink-1, which could circumvent the drug resistance observed in AML cells as well as in 
LSC. In this article, we review recent advances made in identifying the role of different 
components of this pathway in the regulation of HSC and LSC along with possible therapeutic 
approaches.
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Introduction
The mTORC1-S6K1 pathway regulates multiple cellular functions including cell cycle, 
apoptosis, glucose metabolism, protein synthesis and autophagy. This pathway has also been 
identified as one of the critical regulators of HSC and AML cells. Earlier studies have 
primarily examined different activators or repressors of mTORC1 activity in the context of 
hematopoiesis and leukemogenesis (1-4). More recently, multiple studies have identified the 
role(s) of distinct components of mTORC1 and S6K1 in hematopoiesis and leukemogenesis 
including the role of mTORC-S6K1 in regulating self-renewal of LSC (5-8). Here, we 
review the role of mTORC1 and S6K1 in hematopoiesis and AML, and discuss current 
progress towards pharmacological targeting of mTORC1 and S6K1.
Components and signaling of mTORC1-S6K1 pathway
mTOR is a serine/threonine complex that can be divided in two distinct complexes, mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (9). mTORC1 has six and 
mTORC2 has seven protein components (9). Both complexes have the catalytic mTOR 
subunit, mammalian lethal with sec-13 protein 8 (mLST8) and the DEP domain containing 
mTOR-interacting protein (DEPTOR) in common (9) (Figure 1). Furthermore, the telomere 
maintenance 2 (Tel2) and Tel2 interacting protein 1 (Tti1) complex is also necessary for 
assembly of both mTORC1 and mTORC2 (10) (Figure 1). Regulatory-associated protein of 
mammalian target of rapamycin (Raptor) and proline-rich Akt substrate 40 kDa (PRAS40) 
are specific components of mTORC1, whereas rapamycin-insensitive companion of mTOR 
(rictor), mammalian stress-activated map kinase-interacting protein 1 (mSin1), and protein 
observed with rictor 1 and 2 (protor1/2) are part of mTORC2 (9) (Figure 1).
mTORC1 is activated by multiple external inputs including growth factors, nutrients and the 
cellular energy status. Growth factors like insulin activate mTORC1 through the PI3K-Akt 
pathway. Following stimulation by insulin, Akt undergoes PDK1-mediated activation. 
Activated Akt phosphorylates TSC2 and inhibits the formation of TSC complex (11). TSC 
complex acts as a GTPase-activating protein (12) (12) for the small GTPase Ras homologue 
enriched in brain (Rheb), which resides on lysosomal surface (13-15) (Figure 2). Following 
inhibition of TSC complex, GTP-bound Rheb binds to the catalytic domain of mTOR to 
activate mTORC1 (16). Insulin can also activate mTORC1 through Akt-mediated 
phosphorylation of PRAS40 at Thr-246 (17). In contrast, amino acids induce activation of 
mTORC1 through a different pathway. Amino acids facilitate translocation of mTORC1 to 
the lysosomal surface through Rag heterodimer-dependent and independent pathways 
(Figure 2) (18-23). Following translocation of mTORC1 from the cytoplasm to lysosome 
(24), Rheb activates mTORC1 (25). The cellular levels of ATP and AMP are also a critical 
regulator of mTORC1 activation. When cellular energy level is low, the AMP: ATP ratio 
remains high. During high AMP: ATP levels, AMPK phosphorylates TSC2 (14) and Raptor 
(26) to inhibit mTORC1 activity. Conversely, a high ATP:AMP level inhibits activation of 
AMPK (27) (Figure 2). Activated mTORC1 regulates the activity of 4E-BP1 and S6K1 by 
phosphorylating them (Figure 2). mTORC1 phosphorylates 4E-BP1 thus causing its 
dissociation from eukaryotic translation initiation factor 4E (eIF4E). Following dissociation 
of 4E-BP1, eIF4G binds to eIF4E and initiates 5′ cap-dependent translation (27). Activated 
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mTORC1 phosphorylates S6K1, which is a member of cAMP-dependent protein kinases A, 
cGMP-dependent protein kinases G, and phospholipid-dependent protein kinases C (AGC) 
subfamily of serine-threonine kinases (28), at Thr-389 and activates it (29) (Figure 2). 
Following its activation, S6K1 phosphorylates multiple substrates including ribosomal 
protein S6 (RPS6) (30), eukaryotic translation elongation factor 2 kinase (eEF2K) (31), 
S6K1 Aly ⁄ REF-like substrate (SKAR) (32), eukaryotic translation initiation factor 4B 
(eIF4B) (33), and programmed cell death 4 (PDCD4) (34) (Figure 2). Moreover, S6K1 can 
also act as a repressor of mTORC1 pathway by creating a negative feedback loop through its 
regulation of mTORC2 activity (Figure 3). Activated mTORC2 phosphorylates and activates 
Akt at Ser-473. Absence of mTORC2 activity results in reduced phosphorylation of Akt at 
Ser-473 (35). mSin1 and Rictor, two components of mTORC2, are required for mTORC2-
dependent phosphorylation of Akt at Ser-473 (36). S6K1-mediated phosphorylation of 
mSIN1 at Thr-86 and Thr-398 results in dissociation of mSIN1 from mTORC2 thus 
impairing the overall mTORC2 activity (Figure 3) (35). S6K1 can also regulate mTORC2 
activity by phosphorylating Rictor, another component of mTORC2. Following mTORC1-
dependent activation, S6K1 phosphorylates Rictor at Thr-1135 thus inhibiting mTORC2-
mediated Akt activation (37). In addition, S6K1 also inhibits Akt-mTORC1 activity by 
phosphorylating IRS-1 at Ser-302. In response to insulin, insulin receptor substrate-1 
(IRS-1) recruits and subsequently activates phosphoinositide 3-OH kinase (PI3K), an 
upstream regulator of mTORC1-S6K1. Phosphorylation at Ser-302 of IRS-1 by S6K1 results 
in disruption of its interaction with insulin receptor and inhibits PI3K-mediated Akt 
activation (Figure 3) (38).
Pharmacological inhibitors of mTORC1-S6K1
As mTORC-S6K1 pathway is hyperactivated in multiple cancers including hematologic 
malignancies, it has been a critical target for development of pharmacological inhibitors. In 
1999, rapamycin, an allosteric inhibitor of mTORC1, was approved for use as an 
immunosuppressant to prevent rejection following organ transplant (39). In mammalian 
cells, rapamycin interacts with immunophilin FKBP12. The carboxy-terminal region of 
mTOR contains the FKBP-rapamycin binding (FRB) domain and the kinase domain. The 
FKBP12-rapamycin complex docks to the FRB domain and allosterically inhibits the kinase 
activity of mTORC1 (40). Identification of rapamycin as a clinically relevant compound has 
led to the development of semi-synthetic analogues, which are collectively called 
rapalogues. Temsirolimus, everolimus and ridaforolimus are some of the rapalogues, and 
considered as the first generation mTORC1 inhibitors (41-43).
The second generation mTORC1 inhibitors are ATP analogues, which compete with ATP for 
binding to the kinase domain of mTOR and subsequently inhibit the kinase function of 
mTOR. These ATP analogues can inhibit the function of both mTORC1 and mTORC2. 
Moreover, due to the structural similarity between kinase domains of mTOR and PI3K, 
some of the ATP analogues inhibit functions of both mTOR and PI3K. Based on their 
activity against mTOR and PI3K, ATP analogues can be divided into two distinct groups. 
The first group is comprised of inhibitors which show similar efficacy in inhibiting the 
function of both mTOR and PI3K. NVPBEZ235, XL765, GSK2126458, SF1126, BGT226, 
GDC0980, PKI587, PF04691502, GSK2126458 are the inhibitors that belong to the first 
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group (40). The second group of inhibitors are more specific towards inhibiting mTOR 
activity at a significantly lower IC50 than that for PI3K. PP242, INK128 (a derivative of 
PP242), CC223, OSI027, AZD8055, AZD2014, Palomid 529 are the ATP analogues with 
higher efficacy towards inhibiting mTOR activity (40). However, prolonged treatment with 
either rapalogues or ATP analogues led to development of drug resistance in malignant cells 
(44, 45). To overcome drug resistance, a new study has proposed to exploit the juxtaposition 
of both drug-binding pockets in mTORC1 to create a bivalent interaction (46). RapaLink-1 
is a bivalent mTORC1 inhibitor, which was created by linking MLN0128, a structural 
analogue of PP242, using a 39-heavy-link atom linker, with rapamycin (46). Treatment of 
mice bearing either rapalogue-resistant or ATP analogue- resistant tumors with RapaLink-1 
results in reduced tumor growth. RapaLink-1 can inhibit phosphorylation of both S6K1 and 
Akt (Ser-473), thus inhibiting both mTORC1 and mTORC2 activity.
One of the major drawback of rapalogues is that they also inhibit the negative feedback loop 
that S6K1 exerts on IRS-1 (Figure 3), leading to an increase in Akt activation (47). This 
provides strong rationale for development of inhibitors, which can inhibit both mTORC1 
activity and Akt activity simultaneously. To this end, dual S6K1/Akt inhibitors could be 
more useful in treating malignancies. Treatment of breast cancer cells with M2698, a dual 
S6K1/Akt inhibitor, results in the inhibition of both S6K1 and Akt activity (48). Treatment 
with M2698 induces increased phosphorylation of Akt in breast cancer cells due to 
withdrawal of the negative feedback loop exerted by S6K1. However, phosphorylation of 
PRAS40, a substrate of Akt, was not increased under these conditions, suggesting possible 
inhibition of Akt activity. In addition to the dual S6K1/Akt inhibitors, PF-4708671, a 
specific inhibitor of S6K1 activity, also inhibited hyperphosphorylation of Akt following 
S6K1 inhibition (49).
Effect of mTORC1 on steady state hematopoiesis
Multiple studies have established that activity of mTORC1 is critical for the maintenance of 
steady-state hematopoiesis. Deletion of mTOR, a component of both mTORC1 and 
mTORC2, results in reduced white blood cell (WBC) counts in mice, which is associated 
with a reduction in neutrophils and monocytes. Furthermore, deficiency of mTOR also 
causes reduction in platelets and erythrocytes in peripheral blood. Conditional deletion of 
mTOR in HSC led to a reduction in BM cellularity (8). The decrease in BM cellularity was 
due to a reduction in both myeloid and lymphoid cells. Both the myeloid and lymphoid cells 
in BM of mTOR-deficient mice show an increase in apoptosis compared to controls. At the 
molecular level, lineage committed cells in the BM of mTOR-deficient mice display reduced 
expression of Mcl-1, an anti-apoptotic protein.
The role of Raptor, a specific component of mTORC1, in regulating hematopoiesis has been 
studied using two different models (6, 7). Interestingly, effect of Raptor deletion on HSC 
differed depending on the model. In a tamoxifen-inducible model, deletion of Raptor caused 
decreased BM cellularity (6). Differentiated hematopoietic cells (Lin+ and Mac1+Gr1+) 
showed an increase in apoptosis following loss of Raptor. Following administration of 
tamoxifen, Raptor-deficient mice also succumbed to death within 17 days. Moreover, Raptor 
deletion did not affect cell cycle state of any hematopoietic population (6). In contrast, 
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conditional deletion of Raptor using polyinosinic-polycytidylic acid (pI:pC) did not affect 
the BM cellularity (7). In this model, Raptor-deficient mice displayed pancytopenia and 
extramedullary hematopoiesis in the spleen. Raptor-deletion also led to an accumulation of 
monocytes as well as increased level of pro-B cells in mice. Deletion of Raptor specifically 
increased the frequency and proliferation of short-term HSC (ST-HSC) compared to long-
term HSC (LT-HSC) (7). Raptor-deficient LSK cells displayed elevated level of AMP, 
NADP+ and other intermediates involved in lipid metabolism. In addition, Raptor-null HSC 
show decreased level of metabolites involved in nitrogen metabolism (7). Thus, Raptor 
deficiency affects the cellular nutrient status as well as metabolic pathways in HSC. 
Downstream of mTORC1, deficiency of S6K1 in the HSC also results in reduced BM 
cellularity (5). Moreover, the number of HSC are also reduced in S6K1-/- mouse. It is 
possible that S6K1 is a key substrate of mTORC1 in maintaining BM cellularity and 
deficiency of either Raptor or mTORC1 negatively affects BM cellularity.
One of the key properties of HSC is that they reside mostly in a quiescent state (50). This is 
a protective mechanism, which helps to preserve the functional stem cell pool by preventing 
their exhaustion. In HSC, either mTOR or S6K1 activity is required to maintain their 
quiescence. Deficiency of either mTOR or S6K1 in HSC results in reduced frequency of 
HSC in G0 phase of cell cycle (5, 8). Mechanistically, deficiency of mTOR activity in HSC-
enriched population results in reduced activation of S6K1 and increased activation of Akt at 
Ser-473 (8). Moreover, increased activation of Akt is associated with an increase in 
proliferation of HSC (4). As S6K1 exerts an inhibitory feedback loop on Akt, it is possible 
that deficiency of S6K1 activity in HSC causes increased activation of Akt, which 
subsequently leads to a decrease in cellular quiescence. Interestingly, in contrast to lineage-
committed cells, Mcl-1 expression leveli significantly increased in HSC following mTOR 
deletion (8). Moreover, mTORC1 has differential activity in different hematopoietic 
populations. Phosphorylation levels of both S6, a downstream substrate of S6K1, and 4E-
BP1 are low in HSC and high in multipotent progenitors (MPP), common myeloid 
progenitors (CMP) and granulocyte macrophage progenitors (GMP). In contrast, S6 and 4E-
BP1 phosphorylation levels were low in B lymphocytes (6). These results suggest that 
mTORC1 signaling might have a differential effect on the same substrate in different 
hematopoietic populations. Furthermore, evidence suggests that mTORC1 might act on 
different substrates depending on hematopoietic subsets. Deficiency of Raptor results in 
increased phosphorylation of Akt in relatively mature hematopoietic population only (7). 
This indicates that the S6K1-mediated negative feedback loop might exist in specific cell 
type of the BM, which is withdrawn following deletion of Raptor. Multiple studies have 
demonstrated the association of quiescence with functional defects and exhaustion of HSC. 
S6K1-/- HSC have reduced Cdkn1a (the gene encoding p21) expression compared to 
controls (5). Cdkn1a is a critical mediator of HSC quiescence and Cdkn1a-/- HSC undergo 
increased proliferation and exhaust their functional potential upon serial transplantation (51). 
Taken together, it is probable that S6K1-/- HSC are less quiescent due do decrease in 
Cdkn1a expression level. Functionally, HSC are defined by their ability to reconstitute the 
hematopoietic system of irradiated hosts following serial transplantation. Conditional 
deletion of mTOR or Raptor results in reduced engraftment of HSC in primary transplant 
recipients (7, 8). However, loss of expression of S6K1 does not affect the long-term 
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engraftment in primary recipients, but results in reduced self-renewal of HSC in secondary 
and tertiary recipients (5). As activation of mTORC1 results in inactivation of 4E-BP1 and 
activation of S6K1, it is conceivable that both events are required for engraftment of HSC in 
primary recipients. However, S6K1 might be the critical downstream substrate of mTORC1 
and regulates self-renewal of HSC. Expression level of Cdkn1a was significantly down-
regulated in S6K1-/- LSKs isolated from BM of secondary recipients (5). Cdkn1a-deficient 
HSC exhaust upon serial transplant, which suggests a decline in self-renewal potential (51). 
Given that S6K1-/- HSC shows a reduction in Cdkn1a expression and also mirrors the 
functional ability of Cdkn1a-/- HSC, Cdkn1a could be a possible target of mTORC1-S6K1 
signaling in HSC.
By using genetic models, it has been established that loss of mTORC1 activity negatively 
impacts engraftment and self-renewal of HSC in mice (5, 7). However, inhibition of 
mTORC1 activity in HSC by using pharmacological inhibitors in human and murine HSC 
have yielded opposite results compared to genetic approaches. Phenotypically defined 
murine HSC-enriched population is expanded following treatment with rapamycin (52). 
Further, rapamycin treatment increases the long-term engraftment of murine HSC (52). 
Similarly, rapamycin treatment also affects the function of human HSC. Human UCB 
CD34+ cells display an increase in engraftment and self-renewal following treatment with 
rapamycin (53). Simultaneous pharmacological inhibition of GSK3 and mTORC1 also 
increases the self-renewal and engraftment of human HSC (54). Moreover, human HSC 
could maintain their function in cytokine-free culture following pharmacological inhibition 
of GSK3 and mTORC1 (54). It is possible that in HSC, in vitro treatment with rapamycin 
might activate or repress other pathways resulting in increased engraftment following 
transplantation.
Effect of mTORC1 activity in AML
AML is characterized by clonal expansion of early myeloid progenitors. AML patients have 
poor long-term overall survival (OS) and for older patients, the median OS is one year (55). 
One of the major reason for poor outcome in AML is the relapse of the disease. LSC are a 
small population of cells, which can give rise to identical daughter cells as well as 
differentiated cells. LSC have the potential to initiate and maintain AML through serial 
transplantation (56). Recent studies have identified mTORC1-S6K1 pathway as a key 
regulator of LSC maintenance. Rheb1, an activator of mTORC1, is overexpressed in AML 
patients (57). AML patients with increased Rheb1 expression have decreased mean survival 
time compared to patients with low level of Rheb1. Deletion of Rheb1 in a murine model of 
leukemia results in impaired LSC activity. In LSC-enriched population, deletion of Rheb1 
results in reduced mTORC1 activity (57). Moreover, S6K1 and 4E-BP1, the downstream 
substrates of mTORC1, are constitutively phosphorylated in 60% of AML cells isolated 
from patients (58). The phosphorylation level of S6K1 in AML blasts is decreased following 
inhibition of mTORC1 activity, suggesting that S6K1 is a target of mTORC1 in AML cells 
(59). Deficiency of Raptor in AML cells prolonged the survival of mice, which suggests that 
Raptor regulates leukemia initiation. Raptor deletion selectively causes apoptosis in 
differentiated cells. In addition, following serial transplantation of AML cells, Raptor 
deficiency resulted in prolonged survival of recipient mice suggesting that Raptor is a 
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regulator of LSC self-renewal. PTEN deletion in HSC results in hematologic malignancies. 
Deletion of Raptor in PTEN-deficient HSC prolongs the survival of mice (7) indicating 
mTORC1 activity is required for PTEN-deletion induced leukemogenesis as well. 
Deficiency of S6K1 does not affect leukemia initiation or progression. However, S6K1 
deficiency negatively affects the self-renewal potential of LSC and increases the median 
survival time after serial transplantation (5). In contrast to HSC, deficiency of S6K1 results 
in increased quiescence of LSC-enriched population (5). Mechanistically, the 
phosphorylation of 4E-BP1 is significantly decreased in S6K1 deficient AML cells 
indicating S6K1 might regulate mTORC1 activity (5). These findings suggest that S6K1 
might affect LSC function by inhibiting the activity of mTORC1.
Pharmacological inhibition of mTORC1-S6K1 activity in AML
Studies have shown that rapalogues display potent anti-leukemic activity. However, in a 
clinical setting, treatment with rapalogue alone failed to display significant effect in AML 
patients. In a phase I trial of deferolimus, none of the AML patients responded to the drug 
(60). In another phase I/II trial, everolimus also failed to elicit any response in AML 
patients. The rapalogues are considered to be a specific inhibitor of mTORC1 (61). 
However, when rapalogues were used in combination with chemotherapy, a significant 
improvement in median disease free survival and median overall survival was reported (62, 
63). In contrast, a recent study has demonstrated that activation of mTORC1 in AML cells 
could be used as a therapeutic strategy. Sustained mTORC1 activation led to increased 
AMPK activation-mediated cytotoxicity in AML cells (64). The authors proposed that 
AMPK and mTORC1 contribute toward a synthetic lethal interaction in AML cells.
One of the major roadblocks in using rapalogues alone as a therapeutic strategy to treat 
AML is that it leads to withdrawal of S6K1-mediated negative feedback loop involving 
mTORC2. Although mTORC2 is active in AML cells, efficacy of rapalogues in inhibiting 
mTORC2 activity in AML cells has been inconclusive. Treatment of AML patients with 
either everolimus or temsirolimus results in reduced Akt phosphorylation at Ser-473, 
suggesting inhibition of mTORC2 activity (65). Conversely, in another study, treatment of 
primary leukemic blasts with rapamycin failed to attenuate mTORC2 activity (66). The 
differences in the outcomes between these studies could be due to the time of exposure of 
leukemic cells to rapalogues; as studies have shown that only long-term treatment with 
rapalogues results in reduced mTORC2 activity (67). To circumvent mTORC2 activation 
following mTORC1 inhibition, dual inhibitors of mTORC1 and mTORC2 have been 
developed. SNS-032, a dual inhibitor of mTORC1/2, induced cytotoxicity in AML blasts 
isolated from patients (68). However, a group of patients were also not responsive to 
SNS-032. AZD8055, another dual mTORC inhibitor, blocked protein translation and 
proliferation in AML cells (69). AZD8055 also induced autophagy in human AML cells and 
inhibited the initiation of leukemia in vivo (69). In a recent study, treatment of AML cells 
with an anti-CD44 monoclonal antibody showed a decrease in cellular proliferation and 
blocked mTORC1 and mTORC2 activation (70). Inhibition of mTORC1 activity by 
rapalogues also led to upregulation of insulin-like growth factor-1 (IGF-1)-mediated 
activation of PI3-K-Akt pathway (71). Another obstacle of treatment with rapalogues is the 
insensitivity of 4E-BP1 towards rapalogue treatment compared to S6K1. Long-term 
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rapamycin treatment causes rephosphorylation of 4E-BP1, which could possibly counteract 
the effect of mTORC1 inhibition in malignant cells. However, recent data suggest that in 
AML cells, specific inhibition of S6K1 activity could result in decreased phosphorylation of 
4E-BP1. Treatment of human AML cells expressing MLL-AF9 with PF-4708671 results in 
reduced proliferation in vitro and in vivo (5). Phosphorylations of both mTOR and 4E-BP1 
were also decreased in human AML cells treated with PF-4708671 (5). These data argue that 
as 4E-BP1 is a substrate of mTORC1, it is possible that S6K1 also acts as an activator of 
mTORC1 in AML cells. Given the complex nature of feedback signaling loops in mTORC1 
pathway, mTORC1 inhibitors could be a better therapeutic option when used in combination 
with another inhibitor targeting the negative feedback loops.
Future Directions
The mTORC1-S6K1 pathway plays an important role in leukemia initiation, progression and 
as a critical regulator of LSC. This could potentially lead to targeting of this pathway in 
eliminating LSC in AML. However, given the critical role of this pathway in hematopoiesis, 
it is necessary to develop therapeutic strategies, which will not perturb normal hematopoiesis 
but will only target LSC. Moreover, given the existence of inhibitory feedback loops in this 
pathway, it is necessary to take into consideration the impact of prolonged inhibition of this 
pathway in AML cells. In clinical setting, combined inhibition of mTORC1-S6K1 pathway 
along with another target has been proven to be more successful. Moreover, mTORC-S6K1 
pathway has been shown to be a critical regulator of integral cellular processes like 
metabolism and autophagy. Recent findings show that metabolism (72, 73) and autophagy 
(74-76) are critical regulators of LSC maintenance. Additionally, mTORC1-S6K1 pathway 
could also reprogram metabolic pathways in malignant cells to help the cells escape 
glycolysis dependency and become resistance to inhibition of cellular glycolysis (77). 
Moreover, from recent literature, one could argue that mTORC1 and S6K1 signaling could 
be differentially targeted on the basis of the cell type in question, which makes it imperative 
to design therapeutic strategies that would allow targeting of specific cell populations. 
Additionally, S6K1 could act differentially from mTORC1 towards regulating similar 
cellular processes, suggesting that S6K1 might have mTORC1-independent functions. For 
example, mTORC1 acts as an inhibitor of autophagy (78, 79). However, the role of S6K1 in 
regulating autophagy depends on the cellular context (80-84). Additionally, the role of S6K1 
in regulation of autophagy and metabolism in HSC and LSC is not known. In view of the 
above facts, it is important to determine how the components of mTORC1-S6K1 pathway 
regulate these processes in both HSC and LSC.
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Highlights
• mTORC1-S6K1 pathway is dysregulated in acute myeloid leukemia.
• mTORC1 and S6K1 regulates function of leukemia stem cells (LSC).
• mTORC1 and S6K1 are also critical regulators of hematopoietic stem cell 
(HSC) function.
• New generation of mTORC1 inhibitors like RapaLink-1 could be a useful 
therapeutic tool against rapamycin-resistant leukemic cells.
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Figure 1. Components of mTORC1 and mTORC2
mTORC1 has six and mTORC2 has seven protein components. Both complexes have the 
catalytic mTOR subunit, mLST8, DEPTOR, and the Tti1-Tel2 complex in common. Raptor 
and PRAS40 are part of mTORC1 whereas Rictor, mSin1 and Protor1/2 are part of 
mTORC2. mTOR acts as a catalytic serine/threonine kinase while DEPTOR is an inhibitor 
of mTOR activity. The Tti1-Tel2 complex acts as a scaffolding protein, which regulates the 
assembly and stability of mTORC1 and mTORC2. mLST8 binds to mTOR near its kinase 
domain and regulates its function. PRAS40 binds to mTORC1 and acts as an inhibitor of 
mTORC1 activity. Raptor is a scaffolding protein, and it regulates assembly, localization and 
substrate binding of mTORC1. Rictor acts as the scaffolding protein in mTORC2 and 
regulates the assembly and substrate binding of mTORC2. Protor and mSin1 regulate 
mTORC2's interaction with SGK1. Moreover, mSin1 acts as a scaffolding protein regulating 
the assembly of mTORC2. Mechanistic target of rapamycin complex 1, mTORC1; 
mammalian lethal with sec-13 protein 8, mLST8; DEP domain containing mTOR-
interacting protein, DEPTOR; Tel2 interacting protein 1, Tti1; telomere maintenance 2, Tel2; 
regulatory-associated protein of mammalian target of rapamycin, Raptor; proline-rich Akt 
substrate 40 kDa, PRAS40; rapamycin-insensitive companion of mTOR, Rictor; mammalian 
stress-activated map kinase-interacting protein 1, mSin1; protein observed with rictor 1 and 
2, Protor1/2; serum- and glucocorticoid-regulated kinase 1, SGK1.
Ghosh and Kapur Page 15
Exp Hematol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Activators and inhibitors of mTORC1-S6K1 signaling pathway
Growth factors such as insulin activate mTORC1 through the PI3K-Akt pathway. Following 
activation by insulin, insulin receptors stimulate and activate IRS-bound PI3K. Activated 
PI3K converts PIP2 to PIP3 and subsequently binding of PIP3 recruits Akt to the plasma 
membrane. The binding of Akt to PIP3 allows PDK1 to bind with Akt and phosphorylate it 
at Thr-308. Activated Akt phosphorylates TSC2 at multiple sites and inhibits its GAP 
activity on Rheb. Following inhibition of TSC2, Rheb is converted into an active GTP-bound 
state and activates mTORC1. mTORC1 could also be activated by Akt-mediated 
phosphorylation of PRAS40, a component of mTORC1. In presence of amino acids, 
mTORC1 translocates to the lysosomal surface and activated by Rheb. Rag GTPases, which 
form heterodimeric complexes comprised of RagA or RagB bound to RagC or RagD, are 
critical for recruitment of mTORC1 to lysosomal surface. GATOR1 acts as a GAP for 
RagA/B and inhibits the translocation of mTORC1 to lysosome. GATOR2 acts as an 
upstream inhibitor of GATOR1 and subsequently facilitates mTORC1 activation through 
Rag heterodimers. CASTOR1 homodimer and Sestrin2 are negative regulators of GATOR2. 
Sestrin2 binds to GATOR2 and inhibits mTORC1 activation. Following binding of leucine to 
Sestrin2, GATOR2 dissociates from Sestrin2. Similarly, CASTOR1 homodimers bind to 
GATOR2 thus exerting an inhibitory effect. Arginine binds to CASTOR1 homodimers and 
dissociates it from GATOR. Following its dissociation from inhibitory regulators, GATOR2 
inhibits GATOR1 activity and facilitates mTORC1 activation. Glutamine regulates mTORC1 
translocation through Arf1 GTPases, a process which is independent of the Rag GTPases. In 
response to low cellular energy level, AMPK inhibits mTORC1 pathway to limit energy 
consumption as well as to facilitate recovery of cellular energy materials. AMPK 
phosphorylates TSC2 at Ser-1387 and activates its GAP activity, which subsequently 
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converts Rheb into an inactive GDP-bound state. AMPK also phosphorylates Raptor at 
Ser-722 and Ser-792, which results in binding of 14-3-3 protein to Raptor and subsequent 
inactivation of mTORC1. Conversely, a high cellular ATP level inhibits activation of AMPK 
by AMP, which results in withdrawal of AMPK-mediated inhibitory signals on mTORC1 
activation. Activated mTORC1 regulates the activity of 4E-BP1 and S6K1 by 
phosphorylating them. Following its activation, S6K1 phosphorylates multiple substrates 
including RPS6, eEF2K, SKAR, eIF4B and PDCD4. Insulin receptor substrate 1, IRS1; 
phosphoinositide 3-kinase, PI3K; phosphatidylinositol (4,5)-bisphosphate, PIP2; 
phosphatidylinositol (3,4,5)-trisphosphate, PIP3; phosphatase and tensin homologue, PTEN; 
3-phosphoinositide-dependent protein kinase 1, PDK1; tuberous sclerosis complex, TSC; 
TBC1 domain family member 7, TBC1D7; Ras homologue enriched in brain, Rheb; p70 
ribosomal protein kinase 1, S6K1; eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1, 4E-BP1; ribosomal protein S6, RPS6; eukaryotic translation elongation factor 2 
kinase, eEF2K; S6K1 Aly ⁄ REF-like substrate SKAR; eukaryotic translation initiation factor 
4B, eIF4B; programmed cell death 4, PDCD4; adenosine monophosphate, AMP; adenosine 
triphosphate, ATP; AMP-activated protein kinase, AMPK; GAP activity towards Rags, 
GATOR; CASTOR; Leucine, Leu; Arginine, Arg; Glutamine, Gln; ADP-ribosylation factor 
1, Arf1. Adapted and modified from Shimobayashi et al (Ref. 27).
Ghosh and Kapur Page 17
Exp Hematol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Inhibition of mTORC1 activity by S6K1
S6K1 acts as a negative regulator of mTORC1 activity by creating negative feedback loops. 
mSin1 and Rictor, two components of mTORC2, are required for mTORC2-dependent 
phosphorylation of Akt at Ser-473. S6K1-mediated phosphorylation of mSin1 at Thr-86 and 
Thr-398 results in dissociation of mSin1 from mTORC2 thus impairing the overall mTORC2 
activity and subsequently diminishing Akt activation level. S6K1 could also regulate 
mTORC2 activity by phosphorylating Rictor, another component of mTORC2. Following 
mTORC1-dependent activation, S6K1 phosphorylates Rictor at Thr-1135. Phosphorylation 
of Rictor at Thr-1135 results in inhibition of Akt activity. S6K1 also inhibits Akt-mTORC1 
activity by phosphorylating IRS-1 on Ser-302, which results in disruption of the interaction 
between IRS-1 and insulin receptor and subsequent inhibition of PI3K-mediated Akt 
activation. Inhibition of Akt activity, an upstream positive regulator of mTORC1, results in a 
reduction in mTORC1 activation.
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